Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc |
Journal website http://www.jofem.org |
Original Article
Volume 10, Number 1, February 2020, pages 16-22
Control of Glycemia With a Basal-Plus Regimen in People With Type 2 Diabetes Mellitus Insufficiently Controlled by Previous Treatment
Tables
Variables | N | Mean ± SD | Range |
---|---|---|---|
N: number of subjects/available data; SD: standard deviation. Results were reported taking into account available data. Missing data were not counted in the total number of subjects or percentages. | |||
Age (year) | 848 | 59.0 ± 9.4 | 30 - 87 |
Gender | 835 | ||
Female | 444 (53.2%) | - | - |
Male | 391 (46.8%) | - | - |
Height (cm) | 846 | 167.2 ± 8.6 | 142 - 192 |
Weight (kg) | 850 | 76.5 ± 11.8 | 43 - 117 |
Body mass index (kg/m2) | 846 | 27.4 ± 4.0 | 16.7 - 50.0 |
Duration of diabetes (years) | 853 | 10.8 ± 6.7 | 1 - 45 |
Heart rate (bpm) | 823 | 77.3 ± 8.6 | 54 - 128 |
Systolic blood pressure (mm Hg) | 844 | 133.4 ± 14.8 | 93 - 230 |
Diastolic blood pressure (mm Hg) | 838 | 75.6 ± 9.7 | 50 - 120 |
Baseline | 12 weeks | 24 weeks | ||||
---|---|---|---|---|---|---|
N | Units/day | N | Units/day | N | Units/day | |
SD: standard deviation; OD: once daily; BID: twice daily; TID: thrice daily. N: number of subjects/available data. Results were reported taking into account available data. Missing data were not counted in the total number of subjects or percentages. | ||||||
Gla-100 | ||||||
OD | 849 | 20.7 ± 8.5 | 837 | 22.7 ± 8.9 | 815 | 23.5 ± 9.0 |
BID | 2 | 33.0 ± 9.9 | 3 | 28.0 ± 11.1 | 2 | 29.5 ± 9.2 |
Glulisine | ||||||
OD | 725 | 9.7 ± 4.2 | 659 | 10.7 ± 3.9 | 612 | 11.5 ± 4.9 |
BID | 46 | 10.1 ± 4.4 | 120 | 14.4 ± 7.1 | 122 | 14.8 ± 6.9 |
TID | 12 | 10.0 ± 4.5 | 26 | 15.6 ± 9.0 | 54 | 16.6 ± 10.3 |
Baseline (n = 851) | 12 weeks (n = 835) | 24 weeks (n = 809) | |
---|---|---|---|
All differences (means or percentages) between visits are significant (P < 0.001). Confidence intervals at 95% are presented between round brackets. HbA1c: hemoglobin A1c. | |||
HbA1c (%) | 9.50 ± 1.51 | 8.08 ± 1.06 | 7.37 ± 0.88 |
ΔHbA1c (%) | - | -1.42 (-1.53, -1.30) | -2.13 (-2.25, -2.02) |
HbA1c < 7.0% | 0% | 10.2% (8.1, 12.2) | 33.0% (29.7, 36.1) |
HbA1c ≤ 6.5% | 0% | 3.5% (2.3, 4.8) | 14.5% (12.0, 16.9) |
N | Baseline | N | 12 weeks | N | 24 weeks | |
---|---|---|---|---|---|---|
N: number of subjects/available data. Results were reported taking into account available data. Missing data were not counted in the total number of subjects or percentages. FBG: fasting blood glucose; PPBG: postprandial blood glucose. | ||||||
FBG (mg/dL) | 810 | 198 ± 65 | 788 | 148 ± 40 | 769 | 129 ± 32 |
ΔFBG (mg/dL) | - | - | 788 | -57 (-79, -35) | 769 | -88 (-110, -66) |
PPBG (mg/dL) | 674 | 277 ± 72 | 678 | 200 ± 51 | 676 | 168 ± 41 |
ΔPPBG (mg/dL) | - | - | 674 | -78 (-84, -72) | 674 | -108 (-114, -102) |
Treatment | Baseline | 12 weeks | 24 weeks | P |
---|---|---|---|---|
FBG: fasting blood glucose; OAD: oral antihyperglycemic drugs; PPBG: postprandial blood glucose; HbA1c: hemoglobin A1c. | ||||
Basal insulin ± OADs (n = 470) | ||||
HbA1c < 7.0% | 0% | 9.2% | 31.6% | - |
HbA1c ≤ 6.5% | 0% | 3.0% | 12.8% | - |
HbA1c (%) | 9.29 ± 1.40 | 8.06 ± 1.06 | 7.41 ± 0.90 | < 0.001 |
FBG (mg/dL) | 178 ± 63 | 140 ± 39 | 126 ± 32 | < 0.001 |
PPBG (mg/dL) | 264 ± 72 | 191 ± 48 | 163 ± 39 | < 0.001 |
2 OADs (n = 272) | ||||
HbA1c < 7.0% | 0% | 13.3% | 33.2% | - |
HbA1c ≤ 6.5% | 0% | 5.5% | 16.0% | - |
HbA1c (%) | 9.77 ± 1.51 | 8.06 ± 1.03 | 7.37 ± 0.85 | < 0.001 |
FBG (mg/dL) | 223 ± 62 | 158 ± 40 | 134 ± 33 | < 0.001 |
PPBG (mg/dL) | 293 ± 68 | 213 ± 52 | 175 ± 40 | < 0.001 |
Premixed insulin ± OADs (n = 35) | ||||
HbA1c < 7.0% | 0% | 8.6% | 51.4% | - |
HbA1c ≤ 6.5% | 0% | 0.0% | 31.4% | - |
HbA1c (%) | 9.13 ± 1.16 | 7.98 ± 0.93 | 6.98 ± 0.89 | < 0.001 |
FBG (mg/dL) | 199 ± 47 | 148 ± 34 | 122 ± 24 | < 0.001 |
PPBG (mg/dL) | 252 ± 55 | 193 ± 40 | 174 ± 50 | < 0.001 |